PMC:7283670 / 104999-107206
Annnotations
LitCovid_Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1839-1846 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T2 | 1839-1846 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T6 | 1110-1115 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
T7 | 1839-1846 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T202 | 1110-1115 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T559 | 88-96 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T560 | 109-133 | Disease | denotes | Coronavirus disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T561 | 152-161 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T562 | 1961-1969 | Disease | denotes | acidosis | http://purl.obolibrary.org/obo/MONDO_0006022 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T18 | 173-175 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
T19 | 237-238 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T20 | 684-685 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T21 | 1110-1115 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T67786 | 31-37 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T51571 | 223-228 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T6125 | 270-284 | Chemical | denotes | antiviral drug | http://purl.obolibrary.org/obo/CHEBI_36044 |
T40279 | 270-279 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T78450 | 280-284 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T70786 | 303-309 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T85333 | 395-400 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T23407 | 620-625 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T89303 | 660-665 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T51321 | 717-731 | Chemical | denotes | antiviral drug | http://purl.obolibrary.org/obo/CHEBI_36044 |
T61015 | 717-726 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T62050 | 727-731 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T94802 | 750-756 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T11085 | 874-880 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T42076 | 973-979 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T29380 | 1839-1846 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T94147 | 1848-1862 | Chemical | denotes | anticoagulants | http://purl.obolibrary.org/obo/CHEBI_50249 |
T44009 | 2041-2047 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T5062 | 2081-2087 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T18722 | 2120-2126 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T906 | 0-204 | Sentence | denotes | The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: |
T907 | 205-584 | Sentence | denotes | The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days) |
T908 | 585-625 | Sentence | denotes | No intervention: the blank control group |
T909 | 626-820 | Sentence | denotes | All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. |
T910 | 822-996 | Sentence | denotes | Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%) |
T911 | 997-1022 | Sentence | denotes | Secondary (Day −1 to 10): |
T912 | 1023-2207 | Sentence | denotes | The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T292 | 152-161 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T293 | 1083-1090 | Phenotype | denotes | fatigue | http://purl.obolibrary.org/obo/HP_0012378 |
T294 | 1092-1108 | Phenotype | denotes | nausea, vomiting | http://purl.obolibrary.org/obo/HP_0002017 |
T295 | 1110-1125 | Phenotype | denotes | chest tightness | http://purl.obolibrary.org/obo/HP_0031352 |
T296 | 1127-1146 | Phenotype | denotes | shortness of breath | http://purl.obolibrary.org/obo/HP_0002098 |
T297 | 1961-1969 | Phenotype | denotes | acidosis | http://purl.obolibrary.org/obo/HP_0001941 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1868 | 2197-2202 | Gene | denotes | Sep15 | Gene:9403 |
2022 | 74-82 | Species | denotes | patients | Tax:9606 |
2023 | 109-120 | Species | denotes | Coronavirus | Tax:11118 |
2024 | 129-151 | Species | denotes | 2019 novel coronavirus | Tax:2697049 |
2025 | 943-951 | Species | denotes | patients | Tax:9606 |
2026 | 1062-1070 | Species | denotes | patients | Tax:9606 |
2027 | 1263-1271 | Species | denotes | patients | Tax:9606 |
2028 | 1426-1434 | Species | denotes | patients | Tax:9606 |
2029 | 1569-1577 | Species | denotes | patients | Tax:9606 |
2030 | 1712-1720 | Species | denotes | patients | Tax:9606 |
2031 | 1798-1806 | Species | denotes | patients | Tax:9606 |
2032 | 1947-1955 | Species | denotes | patients | Tax:9606 |
2033 | 1997-2005 | Species | denotes | patients | Tax:9606 |
2091 | 1839-1846 | Chemical | denotes | heparin | MESH:D006493 |